Lila Biologics, a burgeoning company that emerged from the prestigious research lab of Nobel Laureate David Baker at the University of Washington, has recently announced an exciting collaboration with pharmaceutical giant Eli Lilly. This partnership aims to pioneer innovative therapies for the treatment of solid tumors, marking a significant milestone for the startup.
Lila has introduced two cutting-edge platforms driven by artificial intelligence and machine learning to revolutionize the creation of therapeutic proteins. One platform is dedicated to targeted radiotherapy, producing proteins that precisely target tumors and deliver radioactive isotopes to eliminate cancer cells. The second platform focuses on developing long-acting injectable drugs that dispense medication gradually over extended periods of time.
The small but dynamic team at Lila is leveraging its targeted radiotherapy technology in the collaboration with Eli Lilly, with the goal of presenting a potential protein candidate within three to six months for further clinical trials by the pharmaceutical giant.
CEO Jake Kraft expressed his enthusiasm for the Eli Lilly partnership, stating, “This collaboration truly showcases our readiness to make a significant impact in the field of medicine. We possess a unique offering and are prepared to advance the development of life-saving drugs.”
Jake Kraft and Chief Scientist Anindya Roy co-founded Lila in 2023 after working together as postdoctoral fellows at the University of Washington’s Institute for Protein Design, under the guidance of Baker.
Renowned for his groundbreaking work in protein engineering, Baker, a Nobel Laureate in chemistry and a co-founder of Lila, has played a pivotal role in developing technology that utilizes AI and ML algorithms to design novel proteins tailored for specific functions, such as drug delivery and environmental remediation.
Lila’s AI tools, inspired by the research at the Institute for Protein Design, have demonstrated remarkable success in creating functional proteins through lab testing, showcasing their potential to streamline the drug development process. Recent publications from the institute have highlighted the technology’s capabilities in designing proteins that target disease markers and complex molecules.
In an effort to foster innovation and collaboration, the Institute for Protein Design has made its foundational AI technology accessible to researchers worldwide at no cost.
In a significant milestone for the company, Lila secured a $10 million seed funding round in 2023, led by WRF Capital, SilverArc Capital Management, and Sahsen Ventures, among others. This financial backing has propelled the company’s research and development efforts, paving the way for future breakthroughs in the field of biotechnology.
For the collaboration with Eli Lilly, Lila’s team is tackling challenging tumor targets that have eluded traditional treatment approaches, showcasing their commitment to addressing unmet medical needs.
Additionally, Lila is advancing its own pipeline of therapies, including a long-acting injectable treatment for pulmonary diseases. With promising candidate drugs in development, the company is gearing up for investigational new drug studies, a crucial step towards human clinical trials.
CEO Jake Kraft emphasized the company’s mission to deliver impactful medicines to patients, stating, “Our goal is not just to design proteins, but to save lives through our innovative therapeutic solutions.”
